As global markets navigate through economic uncertainties, Asian stock markets have shown mixed performances, with some regions experiencing growth while others face challenges. In this environment, identifying undervalued stocks becomes crucial for investors looking to capitalize on potential market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Xiamen Amoytop Biotech (SHSE:688278) | CN¥84.05 | CN¥165.09 | 49.1% |
| Tibet GaoZheng Explosive (SZSE:002827) | CN¥38.57 | CN¥76.72 | 49.7% |
| Takara Bio (TSE:4974) | ¥953.00 | ¥1829.46 | 47.9% |
| Samyang Foods (KOSE:A003230) | ₩1509000.00 | ₩3006664.22 | 49.8% |
| Malee Group (SET:MALEE) | THB5.60 | THB11.01 | 49.1% |
| freee K.K (TSE:4478) | ¥3270.00 | ¥6517.32 | 49.8% |
| Devsisters (KOSDAQ:A194480) | ₩48200.00 | ₩95922.40 | 49.8% |
| Dajin Heavy IndustryLtd (SZSE:002487) | CN¥47.21 | CN¥90.85 | 48% |
| Com2uS (KOSDAQ:A078340) | ₩36500.00 | ₩70061.62 | 47.9% |
| Aecc Aero Science and TechnologyLtd (SHSE:600391) | CN¥28.43 | CN¥54.77 | 48.1% |
Let's dive into some prime choices out of the screener.
LigaChem Biosciences (KOSDAQ:A141080)
Overview: LigaChem Biosciences Inc. is a clinical stage biopharmaceutical company focused on discovering and developing medicines for unmet medical needs, with a market cap of approximately ₩5.55 trillion.
Operations: The company's revenue is derived from two main segments: the Pharmaceutical Business, contributing ₩20.81 billion, and New Drug Research and Development, accounting for ₩127.47 billion.
Estimated Discount To Fair Value: 24.7%
LigaChem Biosciences is currently trading 24.7% below its estimated fair value of ₩202,219.77, suggesting it may be undervalued based on cash flows despite recent financial challenges. The company reported a significant net loss for the second quarter and six months ending June 30, 2025; however, its earnings are forecast to grow at a very large rate annually over the next three years, outpacing market averages significantly.
- According our earnings growth report, there's an indication that LigaChem Biosciences might be ready to expand.
- Click here and access our complete balance sheet health report to understand the dynamics of LigaChem Biosciences.
Akeso (SEHK:9926)
Overview: Akeso, Inc. is a biopharmaceutical company involved in the research, development, manufacture, and commercialization of antibody drugs globally with a market cap of HK$128.78 billion.
Operations: The company's revenue primarily comes from the research, development, production, and sale of biopharmaceutical products, amounting to CN¥2.51 billion.
Estimated Discount To Fair Value: 31.5%
Akeso is trading 31.5% below its estimated fair value of HK$204.02, highlighting potential undervaluation based on cash flows. Despite a net loss of CNY 570.08 million for the first half of 2025, revenue grew to CNY 1.41 billion from CNY 1.02 billion year-over-year, and earnings are expected to grow significantly annually over the next three years as Akeso progresses with innovative clinical trials like ivonescimab and cadonilimab in oncology treatments across Asia and globally.
- The growth report we've compiled suggests that Akeso's future prospects could be on the up.
- Take a closer look at Akeso's balance sheet health here in our report.
Nanya New Material TechnologyLtd (SHSE:688519)
Overview: Nanya New Material Technology Co., Ltd specializes in the manufacturing, design, development, and sale of composite materials with a market cap of CN¥16.81 billion.
Operations: Nanya New Material Technology Co., Ltd's revenue is derived from its activities in manufacturing, designing, developing, and selling composite materials.
Estimated Discount To Fair Value: 10.2%
Nanya New Material Technology Ltd. is trading at CN¥74.5, slightly below its estimated fair value of CN¥82.98, suggesting a modest undervaluation based on cash flows. The company became profitable this year with net income rising to CN¥87.19 million for H1 2025 from CN¥55.29 million a year ago, alongside significant revenue growth of 24% annually projected over the next three years, outpacing market expectations in China despite recent share price volatility and large one-off items impacting results.
- Our expertly prepared growth report on Nanya New Material TechnologyLtd implies its future financial outlook may be stronger than recent results.
- Unlock comprehensive insights into our analysis of Nanya New Material TechnologyLtd stock in this financial health report.
Next Steps
- Access the full spectrum of 279 Undervalued Asian Stocks Based On Cash Flows by clicking on this link.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Akeso might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com